Protocol Builder Launches Individual License Option
Lake Success, NY - Protocol Builder, the cloud-based solution for investigator-initiated clinical trials, is now available to individual researchers, including medical residents and fellows, according to the Biomedical Research Alliance of New York (BRANY), the developer of the system.
“Residents and fellows are often challenged with developing research protocols that meet IRB and regulatory requirements,” says Raffaella Hart, Vice President, IRB and IBC Services. “Protocol Builder provides an easy-to-navigate solution that guides individuals writing research protocols through an intelligent step-by-step process, saving time and effort.”
The tool, originally developed as an enterprise solution, provides simple instructions and relevant tips developed by experts. A built-in Resource Center allows investigators to access protocol samples as well as links to important educational and regulatory information. Users can also download commonly used forms.
With a cloud-based solution, collaboration is easy. Investigators can invite others to review and add comments directly to the appropriate sections.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
